Effects of Miglitol on Daily Plasma Glucose in type2 Diabetes Treated With Insulin

This study has been completed.
Sponsor:
Information provided by:
Sanwa Kagaku Kenkyusho Co., Ltd.
ClinicalTrials.gov Identifier:
NCT00213122
First received: September 13, 2005
Last updated: September 25, 2006
Last verified: September 2006
  Purpose

In this study, the effect of miglitol on daily plasma glucose will be evaluated in type 2 diabetic patients treated with insulin.


Condition Intervention Phase
Type 2 Diabetes Mellitus
Drug: miglitol
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Single Blind
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Sanwa Kagaku Kenkyusho Co., Ltd.:

  Eligibility

Ages Eligible for Study:   20 Years to 74 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • type2 diabetes
  • postprandial plasma glucose levels ≧180mg/dl

Exclusion Criteria:

  • type1 diabetes
  • AST(GOT) or ALT(GPT) ≧100IU/l
  • creatinine ≧2.0mg/dl
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00213122

Locations
Japan
Ibaraki, Japan
Sponsors and Collaborators
Sanwa Kagaku Kenkyusho Co., Ltd.
Investigators
Study Director: Clinical Promotiom Group Sanwa Kagaku Kenkyusho Co., Ltd.
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00213122     History of Changes
Other Study ID Numbers: MG1007
Study First Received: September 13, 2005
Last Updated: September 25, 2006
Health Authority: Japan: Ministry of Health, Labor and Welfare

Keywords provided by Sanwa Kagaku Kenkyusho Co., Ltd.:
alpha-glucosidase inhibitor,Insulin

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Miglitol
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Hypoglycemic Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on April 23, 2014